AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34625784 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 MRDlow (defined as a WT1 MRD ratio ≤2.5% in bone marrow or ≤0.5% in peripheral blood)
Number of subjects: 314
Study 34625784 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic stem cell transplantation (allo-SCT)
Number of subjects: 314
Study 34625784 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD response in patients with intermediate-/unfavorable-risk AML eligible for allo-SCT
Number of subjects: 314
Study 32510976 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided bronchial thermoplasty (BT) after one session
Number of subjects: 30
Study 32510976 — intervention group
Group type: COMPARATOR
Intervention: Unguided bronchial thermoplasty (BT) after three sessions
Number of subjects: 30
Study 34964458 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan 0.16 mg/kg/wk
Number of subjects: 59
Study 34964458 — intervention group
Group type: EXPERIMENTAL
Intervention: Somapacitan (pooled groups)
Number of subjects: 59
Study 34964458 — intervention group
Group type: COMPARATOR
Intervention: Daily GH
Number of subjects: 59
Study 32961500 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day Acceptance and Commitment Therapy workshop
Number of subjects: 430
Study 32961500 — intervention group
Group type: COMPARATOR
Intervention: One-day education and attention control workshop
Number of subjects: 430
Study 34292628 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotility drug
Number of subjects: 77
Study 34292628 — intervention group
Group type: COMPARATOR
Intervention: Surgical patients
Number of subjects: 77
Study 32294244 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF + ABG
Number of subjects: 44
Study 32294244 — intervention group
Group type: COMPARATOR
Intervention: EMD + ABG
Number of subjects: 44
Study 36028825 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition Community Adherence Club (TCAC) intervention
Number of subjects: 16
Study 32712460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF), 1–3 sachets for 8 weeks
Number of subjects: 100
Study 32712460 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 100
Study 35984607 — intervention group
Group type: EXPERIMENTAL
Intervention: DOT Diary (automated directly observed therapy)
Number of subjects: 100
Study 35984607 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 100
Study 33544370 — intervention group
Group type: EXPERIMENTAL
Intervention: Real cerebellar rTMS
Number of subjects: 20
Study 33544370 — intervention group
Group type: COMPARATOR
Intervention: Sham cerebellar rTMS
Number of subjects: 20
Study 32712009 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-pressure gel pads
Number of subjects: 100
Study 32712009 — intervention group
Group type: COMPARATOR
Intervention: Routine institutional policy (Control)
Number of subjects: 100
Study 35102948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-fentanyl
Number of subjects: 80
Study 35102948 — intervention group
Group type: COMPARATOR
Intervention: Propofol-fentanyl
Number of subjects: 80
Study 33839207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting early metastasis (EM) in NPC patients
Number of subjects: 9021
Study 33839207 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 9021
Study 33839207 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold probability of 5.0% for clinical decision-making
Number of subjects: 9021
Study 36397422 — intervention group
Group type: EXPERIMENTAL
Intervention: S2 strategy of deep transfer learning based on DenseNet201
Number of subjects: 8400
Study 36397422 — intervention group
Group type: COMPARATOR
Intervention: S0 strategy of deep transfer learning based on DenseNet201
Number of subjects: 8400
Study 36397422 — intervention group
Group type: COMPARATOR
Intervention: S1 strategy of deep transfer learning based on DenseNet201
Number of subjects: 8400
Study 36397422 — intervention group
Group type: COMPARATOR
Intervention: S3 strategy of deep transfer learning based on DenseNet201
Number of subjects: 8400
Study 33714801 — intervention group
Group type: EXPERIMENTAL
Intervention: NNS on an emptied breast
Number of subjects: 33
Study 33714801 — intervention group
Group type: COMPARATOR
Intervention: NNS pacifier
Number of subjects: 33
Study 32615047 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandarin CV-words
Number of subjects: 40
Study 32615047 — intervention group
Group type: COMPARATOR
Intervention: English nonsense syllables
Number of subjects: 40
Study 35545995 — intervention group
Group type: EXPERIMENTAL
Intervention: delafloxacin 300 mg
Number of subjects: 98
Study 35545995 — intervention group
Group type: COMPARATOR
Intervention: moxifloxacin 400 mg
Number of subjects: 98
Study 33066735 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils
Number of subjects: 30
Study 33066735 — intervention group
Group type: COMPARATOR
Intervention: SensaScope
Number of subjects: 30
Study 35809892 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gadolinium‐enhanced cardiac magnetic resonance (LGE‐CMR) with an image intensity ratio (IIR) threshold of >1.21 for detecting right atrial fibrosis.
Number of subjects: 53
Study 35809892 — intervention group
Group type: EXPERIMENTAL
Intervention: LGE‐CMR with an IIR threshold of >1.29 for differentiating interstitial fibrosis from dense scar.
Number of subjects: 53
Study 35809892 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of IIR values with endocardial bipolar voltage map in patients undergoing AF ablation.
Number of subjects: 53
Study 35809892 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of electroanatomical map and LGE‐CMR for characterizing fibrosis.
Number of subjects: 53
Study 33609794 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF‐α inhibitors
Number of subjects: 134
Study 33609794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 134
Study 33609794 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 134
Study 33609794 — intervention group
Group type: EXPERIMENTAL
Intervention: Janus‐kinase inhibitors
Number of subjects: 134
Study 33609794 — intervention group
Group type: EXPERIMENTAL
Intervention: anti‐IL1 agents
Number of subjects: 134
Study 33175637 — intervention group
Group type: EXPERIMENTAL
Intervention: PER.C6‐based Sabin‐IPV (sIPV, 15:35:112.5 DU/dose)
Number of subjects: 32
Study 33175637 — intervention group
Group type: COMPARATOR
Intervention: Conventional Salk‐IPV (cIPV, 40:8:32 DU/dose)
Number of subjects: 32
Study 33175637 — intervention group
Group type: EXPERIMENTAL
Intervention: PER.C6‐based Sabin‐IPV (sIPV)
Number of subjects: 32
Study 33175637 — intervention group
Group type: COMPARATOR
Intervention: Conventional Salk‐IPV (cIPV)
Number of subjects: 32
Study 34749586 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 40
Study 34749586 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 40
Study 34206188 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Femoral Nerve Block (CFNB)
Number of subjects: 40
Study 34206188 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Femoral Triangle Block (CFTB)
Number of subjects: 40
Study 36459369 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25 µg/day 1 week before parathyroidectomy
Number of subjects: 80
Study 36459369 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Calcitriol)
Number of subjects: 80
Study 34153942 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening of hip abduction (HABD)
Number of subjects: 0
Study 34153942 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening of hip extension (HEXT)
Number of subjects: 0
Study 34153942 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening of hip external rotation (HER)
Number of subjects: 0
Study 34153942 — intervention group
Group type: COMPARATOR
Intervention: Weakness of hip musculature (HABD, HEXT, HER)
Number of subjects: 0
Study 35575012 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly patient-reported outcome—common terminology criteria for adverse event assessments
Number of subjects: 0
Study 35575012 — intervention group
Group type: COMPARATOR
Intervention: Every 6-week assessment of Quality of Life Questionnaire Core 30
Number of subjects: 0
Study 35575012 — intervention group
Group type: COMPARATOR
Intervention: Every 6-week assessment of patient-reported outcome—common terminology criteria for adverse event nausea
Number of subjects: 0
Study 36123858 — intervention group
Group type: EXPERIMENTAL
Intervention: COC1 (20 µg ethinyl estradiol/150 mg desogestrel)
Number of subjects: 127
Study 36123858 — intervention group
Group type: EXPERIMENTAL
Intervention: COC2 (30 µg ethinyl estradiol/3 mg drospirenone)
Number of subjects: 127
Study 36123858 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-users)
Number of subjects: 127
Study 36123858 — intervention group
Group type: EXPERIMENTAL
Intervention: COC1 and COC2
Number of subjects: 127
Study 34185864 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compressions performed in dental chairs (DCs) with structural support designs
Number of subjects: 0
Study 34185864 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compressions performed in dental chairs (DCs)
Number of subjects: 0
Study 34185864 — intervention group
Group type: COMPARATOR
Intervention: Chest compressions performed on the floor
Number of subjects: 0
Study 35014049 — intervention group
Group type: EXPERIMENTAL
Intervention: mOIT with total maintenance dose of 300 mg protein
Number of subjects: 60
Study 35014049 — intervention group
Group type: EXPERIMENTAL
Intervention: mOIT with total maintenance dose of 1200 mg protein
Number of subjects: 60
Study 35014049 — intervention group
Group type: EXPERIMENTAL
Intervention: mOIT with fixed-dose omalizumab
Number of subjects: 60
Study 33046320 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Shears (TS)
Number of subjects: 30
Study 33046320 — intervention group
Group type: COMPARATOR
Intervention: Motorized Diamond Disc Ring Cutter (MDDRC)
Number of subjects: 30
Study 35213488 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated comprehensive children's book
Number of subjects: 80
Study 35213488 — intervention group
Group type: COMPARATOR
Intervention: Conventional consent (Control Group)
Number of subjects: 80
Study 34452934 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose MF/IND (320/150 μg) one time a day
Number of subjects: 3154
Study 34452934 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose MF/IND (160/150 μg) one time a day
Number of subjects: 3154
Study 34452934 — intervention group
Group type: COMPARATOR
Intervention: High-dose FLU/SAL (500/50 μg) two times a day
Number of subjects: 3154
Study 36237123 — intervention group
Group type: EXPERIMENTAL
Intervention: Online gatekeeping service (email-based consultations)
Number of subjects: 167
Study 33609634 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 51
Study 33609634 — intervention group
Group type: EXPERIMENTAL
Intervention: Body massage
Number of subjects: 51
Study 33609634 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study 36294843 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized melanoma genomic risk information
Number of subjects: 0
Study 32173642 — intervention group
Group type: EXPERIMENTAL
Intervention: New wound dressing combined with Longxuejie capsules
Number of subjects: 80
Study 32173642 — intervention group
Group type: COMPARATOR
Intervention: Longxuejie capsules (control group)
Number of subjects: 80
Study 35781026 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (3 mL +200 µg)
Number of subjects: 11
Study 35781026 — intervention group
Group type: COMPARATOR
Intervention: Sham (3 mL of lactate Ringer's solution)
Number of subjects: 11
Study 35781026 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 11
Study 35781026 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 11
Study 33945544 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Number of subjects: 1188
Study 33264686 — intervention group
Group type: EXPERIMENTAL
Intervention: Nike Vaporfly 4% (VP4)
Number of subjects: 18
Study 33264686 — intervention group
Group type: EXPERIMENTAL
Intervention: Saucony Endorphin lightweight racing flats (FLAT)
Number of subjects: 18
Study 33264686 — intervention group
Group type: COMPARATOR
Intervention: Own shoes (OWN)
Number of subjects: 18
Study 35174575 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-Delivered Within My Reach relationship education curriculum and violence screening and referrals
Number of subjects: 119
Study 33852164 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (800 mg total, chewed gum for 5 minutes at 2-hour intervals over a 6-hour treatment period)
Number of subjects: 24
Study 33852164 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chewed gum for 5 minutes at 2-hour intervals over a 6-hour treatment period)
Number of subjects: 24
Study 32315497 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical omiganan 2.5%
Number of subjects: 36
Study 32315497 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel (control)
Number of subjects: 36
Study 32315497 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical omiganan 1%
Number of subjects: 36
Study 36169979 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid prescription fills
Number of subjects: 866586
Study 36169979 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg per day)
Number of subjects: 866586
Study 36169979 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (1 mg per day) duration-response analysis
Number of subjects: 866586
Study 36169979 — intervention group
Group type: COMPARATOR
Intervention: Cyanocobalamin (vitamin B12)
Number of subjects: 866586
Study 34865112 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPP + BAI Booster
Number of subjects: 26231
Study 34865112 — intervention group
Group type: COMPARATOR
Intervention: AMPP + Bystander Intervention
Number of subjects: 26231
Study 35482652 — intervention group
Group type: EXPERIMENTAL
Intervention: ESTEEM (10 sessions)
Number of subjects: 254
Study 35482652 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (HIV testing and counseling, LGBQ-affirmative counseling)
Number of subjects: 254
Study 34484377 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release and stretching techniques (3 sessions, 20 min each)
Number of subjects: 40
Study 33220047 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes
Number of subjects: 752
Study 33220047 — intervention group
Group type: COMPARATOR
Intervention: Normal nicotine content (NNC) cigarettes (control)
Number of subjects: 752
Study 33310419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone tapering (OPT)
Number of subjects: 66
Study 33310419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 32067626 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass azithromycin distribution
Number of subjects: 3
Study 32067626 — intervention group
Group type: COMPARATOR
Intervention: Limiting antibiotic treatment to higher risk children
Number of subjects: 3
Study 35353088 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postextraction implant with bovine bone mineral
Number of subjects: 48
Study 35353088 — intervention group
Group type: COMPARATOR
Intervention: Alveolar ridge preservation technique with implant placement 4 months later
Number of subjects: 48
Study 33785743 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1a (180 mcg subcutaneous dose)
Number of subjects: 120
Study 33785743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 34499193 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-Remifentanil (Group R)
Number of subjects: 100
Study 34499193 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine-Sufentanil (Group S)
Number of subjects: 100
Study 32869590 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Number of subjects: 60
Study 32869590 — intervention group
Group type: COMPARATOR
Intervention: Sham TEAS
Number of subjects: 60
Study 35793180 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL epidural normal saline injection (lapa-saline group)
Number of subjects: 60
Study 35793180 — intervention group
Group type: COMPARATOR
Intervention: No intervention (lapa group)
Number of subjects: 60
Study 35793180 — intervention group
Group type: COMPARATOR
Intervention: No intervention (open group)
Number of subjects: 60
Study 32586702 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mask
Number of subjects: 30
Study 32586702 — intervention group
Group type: COMPARATOR
Intervention: Oronasal mask
Number of subjects: 30
Study 35706617 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (small size endotracheal tube followed by exchange to standard size)
Number of subjects: 80
Study 35706617 — intervention group
Group type: COMPARATOR
Intervention: Group C (standard size endotracheal tube)
Number of subjects: 80
Study 35706617 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S
Number of subjects: 80
Study 35706617 — intervention group
Group type: COMPARATOR
Intervention: Group C
Number of subjects: 80
Study 32088913 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam at 40 mg/kg over 10 min
Number of subjects: 61
Study 32088913 — intervention group
Group type: COMPARATOR
Intervention: Fosphenytoin at 20 mg/kg phenytoin equivalents (PE)
Number of subjects: 61
Study 32088913 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 33962664 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 120
Study 33962664 — intervention group
Group type: COMPARATOR
Intervention: Cultural and recreational activities
Number of subjects: 120
Study 32171647 — intervention group
Group type: EXPERIMENTAL
Intervention: New Zealand blackcurrant extract (NZBC) 600mg (2×300mg/day)
Number of subjects: 18
Study 32171647 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2×300mg microcrystalline cellulose M102)
Number of subjects: 18
Study 33065702 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression socks
Number of subjects: 46
Study 33065702 — intervention group
Group type: COMPARATOR
Intervention: No compression socks (control)
Number of subjects: 46
Study 34295782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium triple viable
Number of subjects: 161
Study 34295782 — intervention group
Group type: EXPERIMENTAL
Intervention: S. boulardii
Number of subjects: 161
Study 34295782 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 161
Study 32826122 — intervention group
Group type: EXPERIMENTAL
Intervention: POCUS
Number of subjects: 162
Study 36396306 — intervention group
Group type: EXPERIMENTAL
Intervention: RCyBorD(x4) induction therapy followed by high-dose melphalan and ASCT, with 12 cycles of Isa maintenance for MRD-negative patients.
Number of subjects: 1400
Study 36396306 — intervention group
Group type: EXPERIMENTAL
Intervention: R, RBorD(x4) + R, RIsa, or RBorIsaD(x4) + RIsa for MRD-positive patients.
Number of subjects: 1400
Study 36396306 — intervention group
Group type: EXPERIMENTAL
Intervention: RBorD(x4) + R or RBorIsaD(x4) + RIsa for high-risk patients.
Number of subjects: 1400
Study 34103179 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel (75 mg/m2)
Number of subjects: 188
Study 34103179 — intervention group
Group type: COMPARATOR
Intervention: cabazitaxel (20 or 25 mg/m2)
Number of subjects: 188
Study 34103179 — intervention group
Group type: COMPARATOR
Intervention: cabazitaxel (20 or 25 mg/m2) in PROSELICA
Number of subjects: 188
Study 34103179 — intervention group
Group type: EXPERIMENTAL
Intervention: plasma lpWGS of ctDNA
Number of subjects: 188
Study 33320753 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid/hydrogel dressings plus 20 exposures to low-level laser therapy (LLLT)
Number of subjects: 43
Study 33320753 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressings alone
Number of subjects: 43
Study 35143744 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue RAASi
Number of subjects: 46
Study 35143744 — intervention group
Group type: COMPARATOR
Intervention: Discontinue RAASi
Number of subjects: 46
Study 34255369 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine (ADH)
Number of subjects: 62
Study 34255369 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir/Hydroxychloroquine (KH)
Number of subjects: 62
Study 32807079 — intervention group
Group type: EXPERIMENTAL
Intervention: Folded replication slippage model
Number of subjects: 55
Study 32807079 — intervention group
Group type: COMPARATOR
Intervention: Existing straight-line slippage model
Number of subjects: 55
Study 35421224 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain version of the BART (pumping the balloon added monetary gains)
Number of subjects: 254
Study 35421224 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss version of the BART (pumping the balloon avoided monetary losses)
Number of subjects: 254
Study 35421224 — intervention group
Group type: EXPERIMENTAL
Intervention: Total performance on the BART
Number of subjects: 254
Study 36057576 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model based on radiomics features of Gd-EOB-DTPA enhanced MRI, tumour margin, and peritumoural hypointensity
Number of subjects: 165
Study 36057576 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model
Number of subjects: 165
Study 36057576 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model
Number of subjects: 165
Study 36057576 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicoradiological model
Number of subjects: 165
Study 36057576 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model based on the combined model
Number of subjects: 165
Study 34521670 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile case management application
Number of subjects: 0
Study 34521670 — intervention group
Group type: COMPARATOR
Intervention: Usual case management practices
Number of subjects: 0
Study 36053806 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir 1600 mg single dose
Number of subjects: 0
Study 36053806 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir 400 mg every 12 hours for 5.5 days
Number of subjects: 0
Study 36053806 — intervention group
Group type: EXPERIMENTAL
Intervention: Molnupiravir 800 mg every 12 hours for 5.5 days
Number of subjects: 0